No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
www.granulesindia.comNo one on the platform currently holds GRANULES.NS.
No tracked institution reports a position in GRANULES.NS as of their last filing.
No one on the platform has traded GRANULES.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.8% | 25.0% | 24.3% | — | — | — |
| Rev. Growth % | 19.7% | 10.6% | ||||
| Profit Margin % | 11.1% | 10.7% | 11.3% | |||
| Free Cash Flow Margin % | 2.2% | 3.2% | -0.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $63.1B | +19.1% | $33.27 | $31.56–$34.94 | — | 6 |
| 2028 | $72.6B | +15.0% | $40.77 | $36.24–$45.58 | — | 7 |
| 2029 | $84.1B | +15.9% | $47.50 | $44.31–$52.30 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-21 | $7.70 | $7.07 | -8.2% |
| 2026-04-29 | $6.05 | $7.66 | +26.6% |
| 2026-01-23 | $5.85 | $6.20 | +6.0% |
| 2025-11-13 | $5.16 | $5.39 | +4.5% |
| 2025-08-12 | $5.30 | $5.70 | +7.5% |
| 2025-05-28 | $5.25 | $5.15 | -1.9% |
| 2025-01-24 | $4.60 | $4.90 | +6.5% |
| 2024-11-06 | $3.85 | $4.00 | +3.9% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| GRANULES.NSGranules India Limited | $872.60 | -4.04% | $216.2B | — |
| APLLTD.BOAlembic Pharmaceuticals Limited | $822.40 | +1.47% | $161.6B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited | $824.75 | +1.70% | $162.1B | — |
| CAPLIPOINT.NSCaplin Point Laboratories Limited | $2570.60 | -6.69% | $195.4B | — |
| INDGN.BOIndegene Limited |
| $571.45 |
| -2.06% |
| $137.8B |
| — |
| INDGN.NSIndegene Limited | $571.50 | -1.18% | $137.7B | — |
| NATCOPHARM.BONATCO Pharma Limited | $819.00 | +0.48% | $146.6B | — |
Source: Financial Modeling Prep · peers by sector/industry